De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders.

The move is the first step of the mitochondrial medicine company’s new strategy to divide its portfolio into two branches: one for common diseases involving mitochondrial dysfunction, the other for rare genetic diseases of mitochondrial origin...